{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:19:40Z","timestamp":1792685980397,"version":"4.5.0"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.phrs.2026.108187","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T06:18:16Z","timestamp":1775197096000},"page":"108187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9861-4139","authenticated-orcid":false,"suffix":"Jr","given":"Robert","family":"Roskoski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2026.108187_bib1","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1542\/peds.9.6.722","article-title":"Agammaglobulinemia","volume":"9","author":"Bruton","year":"1952","journal-title":"Pediatrics"},{"key":"10.1016\/j.phrs.2026.108187_bib2","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/361226a0","article-title":"The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases","author":"Vetrie","year":"1993","journal-title":"Nature 362"},{"key":"10.1016\/j.phrs.2026.108187_bib3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1126\/science.8332900","article-title":"Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes","volume":"261","author":"Thomas","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.phrs.2026.108187_bib4","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1126\/science.8332901","article-title":"Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice","volume":"261","author":"Rawlings","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.phrs.2026.108187_bib5","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0022-3476(62)80092-4","article-title":"A decade with agammaglobulinemia","volume":"60","author":"Bruton","year":"1962","journal-title":"J. Pediatr."},{"key":"10.1016\/j.phrs.2026.108187_bib6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3390\/biom16010123","article-title":"BTK Inhibition in hematology: from CLL\/SLL to emerging applications across B-Cell and immune disorders","volume":"16","author":"Duminuco","year":"2026","journal-title":"Biomolecules"},{"key":"10.1016\/j.phrs.2026.108187_bib7","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.tips.2024.08.006","article-title":"New insights into SYK targeting in solid tumors","volume":"45","author":"Joshi","year":"2024","journal-title":"Trends Pharm. Sci."},{"key":"10.1016\/j.phrs.2026.108187_bib8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton's tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.phrs.2026.108187_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105806","article-title":"Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS","volume":"172","author":"Roskoski","year":"2021","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108187_bib10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbrc.2010.07.092","article-title":"RAF protein-serine\/threonine kinases: structure and regulation","volume":"399","author":"Roskoski","year":"2010","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.phrs.2026.108187_bib11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.phrs.2018.08.013","article-title":"Targeting oncogenic Raf protein-serine\/threonine kinases in human cancers","volume":"135","author":"Roskoski","year":"2018","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108187_bib12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.bbrc.2011.11.145","article-title":"MEK1\/2 dual-specificity protein kinases: structure and regulation","volume":"417","author":"Roskoski","year":"2012","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.phrs.2026.108187_bib13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.phrs.2016.12.009","article-title":"Allosteric MEK1\/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108187_bib14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","article-title":"ERK1\/2 MAP kinases: structure, function, and regulation","volume":"66","author":"Roskoski","year":"2012","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108187_bib15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.phrs.2019.01.039","article-title":"Targeting ERK1\/2 protein-serine\/threonine kinases in human cancers","volume":"142","author":"Roskoski","year":"2019","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108187_bib16","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1084\/jem.20011866","article-title":"The B cell antigen receptor controls integrin activity through Btk and PLC\u03b32","volume":"198","author":"Spaargaren","year":"2003","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.phrs.2026.108187_bib17","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.phrs.2026.108187_bib18","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.bbrc.2004.09.171","article-title":"Src protein-tyrosine kinase structure and regulation","volume":"324","author":"Roskoski","year":"2004","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.phrs.2026.108187_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2015.01.003","article-title":"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors","volume":"94","author":"Roskoski","year":"2015","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108187_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adn6037","article-title":"The crystal and cryo-EM structures of PLC\u03b32 reveal dynamic interdomain recognitions in autoinhibition","volume":"10","author":"Shin","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.phrs.2026.108187_bib21","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1096\/fasebj.9.8.7768349","article-title":"Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification","volume":"9","author":"Hanks","year":"1995","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2026.108187_bib22","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.1862342","article-title":"Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2026.108187_bib23","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1126\/science.1862343","article-title":"Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2026.108187_bib24","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.tibs.2010.09.006","article-title":"Protein kinases: evolution of dynamic regulatory proteins","volume":"36","author":"Taylor","year":"2011","journal-title":"Trends Biochem Sci."},{"key":"10.1016\/j.phrs.2026.108187_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2015.07.010","article-title":"A historical overview of protein kinases and their targeted small molecule inhibitors","volume":"100","author":"Roskoski","year":"2015","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108187_bib26","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1098\/rstb.2012.0054","article-title":"Evolution of the eukaryotic protein kinases as dynamic molecular switches","volume":"367","author":"Taylor","year":"2012","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.phrs.2026.108187_bib27","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.molcel.2004.08.024","article-title":"Regulation of protein kinases; controlling activity through activation segment conformation","volume":"15","author":"Nolen","year":"2004","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phrs.2026.108187_bib28","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1126\/science.271.5250.822","article-title":"Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases","volume":"271","author":"Rawlings","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.phrs.2026.108187_bib29","doi-asserted-by":"crossref","first-page":"17783","DOI":"10.1073\/pnas.0607656103","article-title":"Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism","volume":"103","author":"Kornev","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2026.108187_bib30","doi-asserted-by":"crossref","first-page":"14377","DOI":"10.1073\/pnas.0807988105","article-title":"A helix scaffold for the assembly of active protein kinases","volume":"105","author":"Kornev","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2026.108187_bib31","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Jr, Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108187_bib32","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.phrs.2016.03.012","article-title":"Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108187_bib33","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","article-title":"Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108187_bib34","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.phrs.2017.01.007","article-title":"Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108187_bib35","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.phrs.2017.03.010","article-title":"Jr, Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas","volume":"120","author":"Roskoski","year":"2017","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108187_bib36","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.phrs.2017.04.022","article-title":"ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers","volume":"121","author":"Roskoski","year":"2017","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108187_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2017.12.021","article-title":"Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers","volume":"128","author":"Roskoski","year":"2018","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108187_bib38","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.phrs.2018.01.021","article-title":"The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders","volume":"129","author":"Roskoski","year":"2018","journal-title":"Pharm. Res"},{"issue":"133","key":"10.1016\/j.phrs.2026.108187_bib39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.phrs.2018.04.020","article-title":"Jr, The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders","volume":"133","author":"Roskoski","year":"2018","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108187_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001680","article-title":"Deciphering the structural basis of eukaryotic protein kinase regulation","volume":"11","author":"Meharena","year":"2013","journal-title":"PLoS Biol."},{"key":"10.1016\/j.phrs.2026.108187_bib41","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108187_bib42","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1021\/jm400378w","article-title":"KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space","volume":"57","author":"van Linden","year":"2014","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2026.108187_bib43","doi-asserted-by":"crossref","first-page":"D654","DOI":"10.1093\/nar\/gkab920","article-title":"Kincore: a web resource for structural classification of protein kinases and their inhibitors","volume":"50","author":"Modi","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.phrs.2026.108187_bib44","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.06074","article-title":"Autoinhibition of Bruton's tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate","volume":"4","author":"Wang","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.phrs.2026.108187_bib45","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2026.108187_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70073","article-title":"First line therapy in mantle cell lymphoma-the role of BTKi in the initial treatment of transplant-eligible and -ineligible patients","volume":"43","author":"Silkenstedt","year":"2025","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.phrs.2026.108187_bib47","doi-asserted-by":"crossref","first-page":"48692","DOI":"10.18632\/oncotarget.8961","article-title":"Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents","volume":"7","author":"Inamdar","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2026.108187_bib48","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/17474086.2026.2613730","article-title":"Approaches to the management of relapsed\/refractory mantle cell lymphoma: navigating an increasingly complex therapeutic landscape","volume":"19","author":"Noor","year":"2026","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.phrs.2026.108187_bib49","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrc.2016.8","article-title":"The molecular pathogenesis of chronic lymphocytic leukaemia","volume":"16","author":"Fabbri","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2026.108187_bib50","doi-asserted-by":"crossref","first-page":"68","DOI":"10.6004\/jnccn.2026.0012","article-title":"NCCN Guidelines\u00ae insights: chronic lymphocytic leukemia\/small lymphocytic lymphoma, Version 2.2026","volume":"24","author":"Wierda","year":"2026","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"10.1016\/j.phrs.2026.108187_bib51","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1158\/1078-0432.CCR-14-2225","article-title":"FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia","volume":"21","author":"de Claro","year":"2015","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.phrs.2026.108187_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2026.105239","article-title":"Systematic review of real-world data on the effectiveness and safety profiles of first-line therapies in chronic lymphocytic leukemia","volume":"221","author":"Sto\u017cek-Tutro","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.phrs.2026.108187_bib53","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/leu.2014.263","article-title":"Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors","volume":"29","author":"Cheng","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.phrs.2026.108187_bib54","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.70987","article-title":"The direction of modern therapies in Waldenstr\u00f6m macroglobulinaemia","volume":"29","author":"Blackmore","year":"2025","journal-title":"J. Cell Mol. Med"},{"key":"10.1016\/j.phrs.2026.108187_bib55","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2026.108187_bib56","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70071","article-title":"Diagnosis and management of Waldenstrom's macroglobulinemia","volume":"43","author":"Treon","year":"2025","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.phrs.2026.108187_bib57","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/ajh.27666","article-title":"Waldenstr\u00f6m macroglobulinemia: 2025 update on diagnosis, risk stratification, and management","volume":"100","author":"Gertz","year":"2025","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.phrs.2026.108187_bib58","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1080\/14796694.2025.2558351","article-title":"Zanubrutinib in the treatment of Waldenstr\u00f6m macroglobulinemia","volume":"21","author":"Goodall","year":"2025","journal-title":"Future Oncol."},{"key":"10.1016\/j.phrs.2026.108187_bib59","first-page":"1","article-title":"Patient medication preferences in follicular lymphoma in the United States: a discrete choice experiment","author":"Gaballa","year":"2026","journal-title":"Post. Med"},{"key":"10.1016\/j.phrs.2026.108187_bib60","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3390\/cancers18030395","article-title":"Guidelines for diagnosis, treatment, and follow-up of patients with follicular lymphoma-Spanish lymphoma group (GELTAMO) 2025","volume":"18","author":"Pe\u00f1alver","year":"2026","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2026.108187_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2025.12.013","article-title":"SOHO state of the art updates and next questions: how should we risk stratify and tailor therapy for patients with high tumor burden follicular lymphoma? A systematic review","author":"Akkad","year":"2026","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.phrs.2026.108187_bib62","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/ejh.70105","article-title":"Chemotherapy-sparing strategies in follicular lymphoma: emerging targeted and immune-based approaches","volume":"116","author":"Martino","year":"2026","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.phrs.2026.108187_bib63","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.70170","article-title":"Covalent Bruton tyrosine kinase inhibitors across generations: a focus on zanubrutinib","volume":"29","author":"Broccoli","year":"2025","journal-title":"J. Cell Mol. Med"},{"key":"10.1016\/j.phrs.2026.108187_bib64","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMra2102568","article-title":"Marginal-zone lymphomas","volume":"386","author":"Rossi","year":"2022","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2026.108187_bib65","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.clml.2025.02.002","article-title":"SOHO state of the art updates and next questions: treatment options for marginal zone lymphoma","volume":"25","author":"Pirosa","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.phrs.2026.108187_bib66","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/blood.2024028269","article-title":"The treatment of marginal zone lymphoma","volume":"147","author":"Alderuccio","year":"2026","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2026.108187_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2025.102654","article-title":"Approved and emerging therapies for glucocorticoid-refractory chronic graft-versus-host disease","volume":"97","author":"Zhang","year":"2025","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.phrs.2026.108187_bib68","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/MOH.0000000000000893","article-title":"New molecules in the therapy of chronic graft-versus-host disease","volume":"32","author":"Steiner","year":"2025","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.phrs.2026.108187_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0290872","article-title":"Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib","volume":"18","author":"Lin","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2026.108187_bib70","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood.2019852368","article-title":"Acalabrutinib for mantle cell lymphoma","volume":"133","author":"Witzig","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2026.108187_bib71","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2217\/fon-2018-0637","article-title":"Acalabrutinib and its use in treatment of chronic lymphocytic leukemia","volume":"15","author":"Khan","year":"2019","journal-title":"Future Oncol."},{"key":"10.1016\/j.phrs.2026.108187_bib72","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13045-016-0250-9","article-title":"Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor","volume":"9","author":"Wu","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.phrs.2026.108187_bib73","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.critrevonc.2019.02.001","article-title":"Management of adverse effects\/toxicity of ibrutinib","volume":"136","author":"Paydas","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.phrs.2026.108187_bib74","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1124\/mol.116.107037","article-title":"Ability of Bruton's tyrosine kinase inhibitors to sequester Y551 and prevent phosphorylation determines potency for inhibition of Fc Receptor but not B-cell receptor signaling","volume":"91","author":"Bender","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.phrs.2026.108187_bib75","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-025-01434-2","article-title":"First-line treatment for CLL in the era of targeted therapy","volume":"16","author":"Davids","year":"2026","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.phrs.2026.108187_bib76","first-page":"62","article-title":"Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor","author":"Gomez","year":"2023","journal-title":"Blood 142"},{"key":"10.1016\/j.phrs.2026.108187_bib77","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1021\/acs.jmedchem.9b01916","article-title":"Discovery of LOU064 (remibrutinib), a potent and highly selective covalent inhibitor of Bruton's tyrosine kinase","volume":"63","author":"Angst","year":"2020","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2026.108187_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108187_bib79","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s12272-025-01546-0","article-title":"BTK inhibitors and next-generation BTK-targeted therapeutics for B-cell malignancies","volume":"48","author":"Kim","year":"2025","journal-title":"Arch. Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108187_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2026.108107","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2026 update","volume":"224","author":"Roskoski","year":"2026","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108187_bib81","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40265-025-02259-w","article-title":"Rilzabrutinib: first approval","volume":"86","author":"Lee","year":"2026","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2026.108187_bib82","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1021\/acs.jmedchem.1c01170","article-title":"Discovery of reversible covalent Bruton's tyrosine kinase inhibitors PRN473 and PRN1008 (rilzabrutinib)","volume":"65","author":"Owens","year":"2022","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2026.108187_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(19)30523-6","article-title":"Zanubrutinib in B-cell malignancies","volume":"20","author":"Das","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2026.108187_bib84","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40265-019-01252-4","article-title":"Zanubrutinib: first approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2026.108187_bib85","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton's tyrosine kinase","volume":"63","author":"Guo","year":"2019","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2026.108187_bib86","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1358\/dot.2020.56.8.3158047","article-title":"Zanubrutinib: a new BTK inhibitor for treatment of relapsed\/refractory mantle cell lymphoma","volume":"56","author":"Weaver","year":"2020","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.phrs.2026.108187_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105422","article-title":"Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs)","volume":"165","author":"Roskoski","year":"2021","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108187_bib88","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.chembiol.2012.12.006","article-title":"Developing irreversible inhibitors of the protein kinase cysteinome","volume":"20","author":"Liu","year":"2013","journal-title":"Chem. Biol."},{"key":"10.1016\/j.phrs.2026.108187_bib89","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1021\/jm101396q","article-title":"Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors","volume":"54","author":"Leproult","year":"2011","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2026.108187_bib90","doi-asserted-by":"crossref","first-page":"13408","DOI":"10.1002\/anie.201601091","article-title":"Targeted covalent inhibitors for drug design","volume":"55","author":"Baillie","year":"2016","journal-title":"Angew. Chem. Int Ed."},{"key":"10.1016\/j.phrs.2026.108187_bib91","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.drudis.2018.01.035","article-title":"Progress with covalent small-molecule kinase inhibitors","volume":"23","author":"Zhao","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2026.108187_bib92","doi-asserted-by":"crossref","first-page":"9517","DOI":"10.1021\/acs.jcim.4c00890","article-title":"Exploring extended warheads toward developing cysteine-targeted covalent kinase inhibitors","volume":"64","author":"Zhao","year":"2024","journal-title":"J. Chem. Inf. Model"},{"key":"10.1016\/j.phrs.2026.108187_bib93","article-title":"Probing the protein kinases' cysteinome by covalent fragments","volume":"64","author":"Wang","year":"2025","journal-title":"Angew. Chem. Int Ed. Engl."},{"key":"10.1016\/j.phrs.2026.108187_bib94","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/d41573-025-00188-7","article-title":"FDA approves 100th small-molecule kinase inhibitor","volume":"24","author":"Mullard","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2026.108187_bib95","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.phrs.2017.02.005","article-title":"Guidelines for preparing color figures for everyone including the colorblind","volume":"119","author":"Roskoski","year":"2017","journal-title":"Pharm. Res"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826001027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826001027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T22:32:17Z","timestamp":1778020337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826001027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":95,"alternative-id":["S1043661826001027"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108187","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108187","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108187"}}